





PHARMACEUTICAL 2018

Kura Oncology Inc.
Rank 80 of 342

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Kura Oncology Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 137% points above the market average of 46%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 94,641 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 10,031 |
| Liabilities, Non-Current | 5,955 |
| Other Assets | 1,200 |
| Other Compr. Net Income | -31 |
| Other Expenses | 36,077 |
| Other Liabilities | 0 |
| Other Net Income | 643 |
| Other Revenues | 0 |
| Property and Equipment | 10 |
| Research and Development | 0 |
| Selling, General and Administrative Expense | 0 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 95,851 |
| Liabilities | 15,986 |
| Expenses | 36,077 |
| Revenues | 0 |
| Stockholders Equity | 79,865 |
| Net Income | -35,434 |
| Comprehensive Net Income | -35,450 |
| Economic Capital Ratio | 182% |